Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs Stryker Corporation — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $48.73 (market cap $3.14B), while Stryker Corporation trades at $278.54 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 33.8× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Stryker Corporation pays a 1.27% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 125 Days and Stryker Corporation for 20 Days on average.
| SPHD | SYK | |
|---|---|---|
Market Cap | $3.14B | $106.24B |
Volume | 1,461,349 | 2,982,001 |
52-Week High | $53.55 | $388.35 |
52-Week Low | $46.96 | $269.75 |
Typical Hold Time | 125 Days | 20 Days |
Sector | — | Health |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $48.19, down 0.58% on the day, with a bearish technical signal driven by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income but facing criticism for weaker total returns compared to peers like SCHD. Recent dividends of $0.20 and $0.21 were declared for 2026, emphasizing its income-oriented strategy.
Outlook is cautious due to underperformance risks and lack of quality filters in stock selection. Opportunities include reliable monthly dividends for retirees, but risks involve yield traps and market volatility. Investors should weigh income needs against growth potential.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
